23 November 2017
News and Views
Links and Services
A study in March's issue of the Alimentary Pharmacology & Therapeutics investigates indicators for maintained response or remission to infliximab in patients with Crohn's disease.
Secondary loss of response to anti-TNF-α therapy is observed in Crohn's disease patients.
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors